(Q37071255)

18 August 2017

1 reference

title

Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications (English)

1 reference

Evanthia Diamanti-Kandarakis

18 August 2017

1 reference

series ordinal

1

object named as

Evanthia Diamanti-Kandarakis

1 reference

18 August 2017

30 January 2008

1 reference

Expert Reviews in Molecular Medicine

18 August 2017

1 reference

18 August 2017

10

1 reference

18 August 2017

e3

1 reference

Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome.

18 August 2017

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Should patients with polycystic ovarian syndrome be treated with metformin?: an enthusiastic endorsement

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

The optimal diet for women with polycystic ovary syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Adipocyte resistin mRNA levels are down-regulated by laparoscopic ovarian electrocautery in both obese and lean women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Resistin stimulation of 17alpha-hydroxylase activity in ovarian theca cells in vitro: relevance to polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Serum resistin levels in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Insulin and oxidative stress modulate proliferation of rat ovarian theca-interstitial cells through diverse signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Low grade chronic inflammation in women with polycystic ovarian syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Free fatty acids increase androgen precursors in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Molecular mechanisms of insulin resistance and associated diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Flutamide-metformin therapy to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: effects in adolescents and in women on third-generation oral contraception

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Fat distribution in non-obese girls with and without precocious pubarche: central adiposity related to insulinaemia and androgenaemia from prepuberty to postmenarche.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Developmental origin of polycystic ovary syndrome - a hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Enhanced mitogenic signaling in skeletal muscle of women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Differential gene expression profile in omental adipose tissue in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Amelioration of insulin resistance in women with PCOS via reduced insulin receptor substrate-1 Ser312 phosphorylation following laparoscopic ovarian electrocautery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Preliminary evidence of glycogen synthase kinase 3 beta as a genetic determinant of polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Molecular mechanisms of insulin resistance in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

The insulin resistant subphenotype of polycystic ovary syndrome: clinical parameters and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Subcutaneous adipocytes from obese hyperinsulinemic women with polycystic ovary syndrome exhibit normal insulin sensitivity but reduced maximal insulin responsiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Cellular mechanisms of insulin resistance in polycystic ovarian syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

The prevalence and features of the polycystic ovary syndrome in an unselected population

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

The oocyte and its role in regulating ovulation rate: a new paradigm in reproductive biology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Relationship between serum müllerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Reduced intrafollicular androstenedione and estradiol levels in early-treated prenatally androgenized female rhesus monkeys receiving follicle-stimulating hormone therapy for in vitro fertilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Effects of androstenedione, insulin and luteinizing hormone on steroidogenesis in human granulosa luteal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Androgens augment the mitogenic effects of oocyte-secreted factors and growth differentiation factor 9 on porcine granulosa cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Androgens promote insulin-like growth factor-I and insulin-like growth factor-I receptor gene expression in the primate ovary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Stockpiling of transitional and classic primary follicles in ovaries of women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Insulin alters the effects of follicle stimulating hormone on aromatase in bovine granulosa cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Follicle luteinization in hyperandrogenic follicles of polycystic ovary syndrome patients undergoing gonadotropin therapy for in vitro fertilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Selective ovary resistance to insulin signaling in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

The role of mitogen-activated protein kinase in insulin and insulin-like growth factor I (IGF-I) signaling cascades for progesterone and IGF-binding protein-1 production in human granulosa cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Insulin and messenger ribonucleic acid expression of insulin receptor isoforms in ovarian follicles from nonhirsute ovulatory women and polycystic ovary syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Evidence for abnormal granulosa cell responsiveness to follicle-stimulating hormone in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Administration of dihydrotestosterone to rhesus monkeys inhibits gonadotropin-stimulated ovarian steroidogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Early ovarian ageing: are women with polycystic ovaries protected?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Prolonged survival in culture of preantral follicles from polycystic ovaries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Formation and early development of follicles in the polycystic ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Ovarian and adrenal function in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Stability of adrenocortical steroidogenesis over time in healthy women and women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Serum inhibin B in polycystic ovary syndrome: regulation by insulin and luteinizing hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Insulin Augmentation of 17α-Hydroxylase Activity Is Mediated by Phosphatidyl Inositol 3-Kinase But Not Extracellular Signal-Regulated Kinase-1/2 in Human Ovarian Theca Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Mevastatin inhibits proliferation of rat ovarian theca-interstitial cells by blocking the mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Alterations in mitogen-activated protein kinase kinase and extracellular regulated kinase signaling in theca cells contribute to excessive androgen production in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Protein phosphatase 2A and phosphoprotein SET regulate androgen production by P450c17

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Cytochrome b(5) modulation of 17{alpha} hydroxylase and 17-20 lyase (CYP17) activities in steroidogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Regulation of 17,20 lyase activity by cytochrome b5 and by serine phosphorylation of P450c17

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Flutamide suppresses adrenal steroidogenesis but has no effect on insulin resistance and secretion and lipid levels in overweight women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Dysregulation of cytochrome P450 17alpha-hydroxylase messenger ribonucleic acid stability in theca cells isolated from women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Molecular profiling of polycystic ovaries for markers of cell invasion and matrix turnover.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Retinoids and retinol differentially regulate steroid biosynthesis in ovarian theca cells isolated from normal cycling women and women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Human ovarian theca cells in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Increased cytochrome P450 17alpha-hydroxylase promoter function in theca cells isolated from patients with polycystic ovary syndrome involves nuclear factor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

The molecular signature of polycystic ovary syndrome (PCOS) theca cells defined by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Clomiphene, Metformin, or Both for Infertility in the Polycystic Ovary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Metformin directly inhibits androgen production in human thecal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Metformin administration improves endothelial function in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Effects of metformin on early pregnancy loss in the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Metformin in polycystic ovary syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Polycystic ovary syndrome in post-menopausal women--marker of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Accumulation of dietary glycotoxins in the reproductive system of normal female rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Human glycated albumin affects glucose metabolism in L6 skeletal muscle cells by impairing insulin-induced insulin receptor substrate (IRS) signaling through a protein kinase C alpha-mediated mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Advanced glycation in health and disease: role of the modern environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

In vitro evidence that hyperglycemia stimulates tumor necrosis factor-alpha release in obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Induction of insulin resistance by androgens and estrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Depot differences in steroid receptor expression in adipose tissue: possible role of the local steroid milieu

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Obesity and the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

Serum levels of inhibins are differentially altered in patients with polycystic ovary syndrome: effects of being overweight and relevance to hyperandrogenism

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

7 January 2021

Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

7 January 2021

Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

7 January 2021

Dihydrotestosterone inhibits granulosa cell proliferation by decreasing the cyclin D2 mRNA expression and cell cycle arrest at G1 phase

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

7 January 2021

Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

7 January 2021

Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

7 January 2021

Correlation of adrenocorticotropin steroid levels between women with polycystic ovary syndrome and their sisters

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

7 January 2021

Aberrant expression of growth differentiation factor-9 in oocytes of women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

7 January 2021

Tumor necrosis factor-alpha stimulates proliferation of rat ovarian theca-interstitial cells

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

7 January 2021

Commentary: Polycystic ovary syndrome--increased or preserved ovarian sensitivity to insulin?

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

7 January 2021

Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

7 January 2021

The distribution of betaglycan protein and mRNA in rat brain, pituitary, and gonads: implications for a role for betaglycan in inhibin-mediated reproductive functions

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

7 January 2021

The adipose tissue metabolism: role of testosterone and dehydroepiandrosterone

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

7 January 2021

Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

7 January 2021

Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

7 January 2021

Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS).

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

7 January 2021

Stage-specific expression of androgen receptor, follicle-stimulating hormone receptor, and anti-Müllerian hormone type II receptor in single, isolated, human preantral follicles: relevance to polycystic ovaries

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

7 January 2021

Distinct regulation by steroids of messenger RNAs for FSHR and CYP19A1 in bovine granulosa cells

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

7 January 2021

Polycystic ovary syndrome: the influence of environmental and genetic factors

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

7 January 2021

The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

7 January 2021

Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

7 January 2021

Clinical evidence for an LH 'ceiling' effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

7 January 2021

Pathophysiology and types of dyslipidemia in PCOS.

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

7 January 2021

Obesity and androgens: facts and perspectives

1 reference

https://api.crossref.org/works/10.1017%2FS1462399408000598

7 January 2021

10.1017/S1462399408000598

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18230193